Artificial macrocycles as IL-17A/IL-Web: 17RA antagonists. Issue 1 (15th November 2017)

• Record Type: Journal Article
• Authors: Wang, Wenjia; Groves, Matthew R.; Dömling, Alexander
• Is Part Of: MedChemComm. Volume 9:Issue 1(2018)
• Page Start: 22
• Page End: 26
• Publication Date: 2017-11-15
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c7md00464h
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Abstract : Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL-17(A) or its receptor (IL-Web:17RA ) that show efficacy in clinical trials are monoclonal antibodies (mAbs). However, recently designed artificial macrocycles are potent IL-17A/IL-; Web:17RA antagonists. Based on co-crystal structures, a better understanding of the biological activity and SAR of the macrocycles has been gained, demonstrating that they can compete with mAbs for difficult targets such as PPIs.